DUBLIN – In a final flourish to its first year of trading, Idorsia Ltd., the Swiss firm spun out of Actelion Ltd., banked a massive $230 million milestone as Johnson & Johnson Co. pulled the trigger on an option to co-develop its phase II hypertension drug aprocitentan (ACT-132577).